Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.62 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.62 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.62 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.62 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.62 |
| ▸ | DRD1 | P21728 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | DRD4 | P21917 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1596097 | 0.99 | ADRA2A (0.61) | ADRA2AADRA2BADRA2CHTR2CSLC6A3 | |
| Bromide SCHEMBL1596493 | 0.92 | ADRA2A (0.67) | ADRA2AADRA2BADRA2CHTR2CSLC6A3 | |
| Bromide SCHEMBL1599375 | 0.91 | ADRA2A (0.60) | ADRA2AADRA2BADRA2CHTR2CSLC6A3 | |
| SCHEMBL1597249 | 0.91 | ADRA2A (0.67) | ADRA2AADRA2BADRA2CHTR2CSLC6A3 | |
| SCHEMBL1598287 | 0.90 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CHTR2CSLC6A3 | |
| SCHEMBL1597231 | 0.90 | ADRA2A (0.63) | ADRA2AADRA2BADRA2CHTR2CSLC6A3 | |
| SCHEMBL1597586 | 0.90 | ADRA2A (0.66) | ADRA2AADRA2BADRA2CHTR2CSLC6A3 | |
| Hydrochloric Acid SCHEMBL1598513 | 0.89 | ADRA2A (0.62) | ADRA2AADRA2BADRA2CHTR2CSLC6A3 | |
| Hydrochloric Acid SCHEMBL1598427 | 0.89 | ADRA2A (0.64) | ADRA2AADRA2BADRA2CHTR2CSLC6A3 | |
| SCHEMBL1596848 | 0.88 | ADRA2A (0.61) | ADRA2AADRA2BADRA2CHTR2CSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919508-B2 | 3-piperidinylisochroman-5-ols as dopamine agonists | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-1749001-B1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMA INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-20070099955-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099955-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | DRD3, DRD2, DRD4 | ADRA2A 31/4885ADRA2B 43/4885ADRA2C 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.